SDS Biotech sales reached 14,988 million yen in FY 2017

Consolidated net sales of Japanese company, SDS Biotech, were 14,988 million yen in the fiscal year ended March 31st 2017. According to the company, from the fiscal year ended March 2016, the Company changed its fiscal year-end from December 31 to March 31. Accordingly, year-on-year changes for the fiscal year ended March 2017 (from April 1, 2016 to March 31, 2017) are not stated, because the fiscal year ended March 2017 covers a different period from the comparable fiscal year ended March 2016 (from January 1, 2015 to March 31, 2016). In line with the change of fiscal year-end (last day of a fiscal year) from December 31 to March 31, the fiscal year ended March 2016 consists of 15 months from January 1, 2015 to March 31, 2016. Therefore, year-on-year changes for the fiscal year ended March 2016 are not stated.

 

Consolidated operating income totaled 734 million yen, consolidated ordinary income was 561 million yen and consolidated net loss attributable to owners of parent came to 203 million yen. 

 

SDS Biotech saw a slowdown in shipments due to delays in the shift to new Benzobicyclon mixtures in the paddy herbicide field in Japan and in the registration of agrochemicals outside Japan. This was despite robust shipments of the Company’ mainstay product Daconil technical and its intermediate IPN, attributable to a global increase in demand for Daconil. In addition, SDS Ramcides CropScience Private Limited, a consolidated subsidiary in India, reported a loss due to sluggish net sales caused by the impact of inventory adjustments for unfavorable weather in the previous period and low occurrence of pests. As a result, its liabilities exceeded its assets by 497 million yen. Since this had caused significant deviation from the sales plan developed at the time of acquisition, the Group recognized an impairment loss on goodwill on a consolidated basis, recording an impairment loss of 778 million yen as extraordinary losses. 

Sales result by product
 

Consolidated net sales of fungicides for the fiscal year were 5,700 million yen. The main products were Daconil products (technical and formulation) for markets in Japan and overseas. 

 

Sales of paddy herbicides were 3,862 million yen. The main products were Benzobicyclon technical for markets in Japan and overseas and Daimuron technical for Japan. 

 

Sales of greenery-related products & upland herbicides were 2,720 million yen. The main products were Karbutilate products, Chlorate products for markets in Japan and Dacthal technical for overseas. 

 

Sales of insecticides were 1,809 million yen. The main products were D-D products and biological products (Tune-up). 

 

Sales of other products were 894 million yen. The main products were Daconil intermediate (IPN) and functional fertilizers sold by our consolidated subsidiary in India. 

 

 

Domestic sales accounted for 45.8% of SDS total income in the fiscal year, while overseas sales came in at 8,122 million yen, accounting for 54.2% of the total. Sales in Asia reached 6,345 million yen, and sales in Europe and America were 1,398 million yen. The other oversea regions contributed 377 million yen to the company’s sales.

 

 

In the full-year earnings forecasts, net sales are 15,860 million yen, operating income is 1,440 million yen, ordinary income is 1,320 million yen, and net income attributable to owners of parent is 630 million yen.